Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions

This study has been completed.
Bristol-Myers Squibb
Information provided by:
Sanofi Identifier:
First received: July 7, 2006
Last updated: January 18, 2008
Last verified: January 2008

July 7, 2006
January 18, 2008
February 2005
Not Provided
Microvascular reactivity
Same as current
Complete list of historical versions of study NCT00350038 on Archive Site
  • Reach of target blood pressure
  • Measurements of safety laboratory parameters
Same as current
Not Provided
Not Provided
Irbesartan, Ciprofibrate and Their Combination Onto the Endothelial Functions
Investigations of the Effects of Aprovel, Lipanor and Their Combination Onto the Endothelial Functions of Dyslipidemic Patients Measure by Laser Doppler Flow-Metry.
The rationale of the study is to clarify whether the supplementation of irbesartan with ciprofibrate could increase the antihypertensive effect, could improve the endothelial functions, and/or could affect the atherogenic small-dense LDL-, oxydized LDL concentrations, onto the paraoxinase activity and on the CRP and insulin levels.
Not Provided
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Hypertension
  • Dyslipidemia
  • Drug: Irbesartan
  • Drug: Ciprofibrate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2007
Not Provided

Inclusion Criteria:

  • hypertensive + dyslipidemic + damaged endothelial function

Exclusion Criteria:

  • hepatic and kidney damage,
  • IDDM (Insulin Dependent Diabetes Mellitus)
  • Freckson V type hyperlipoproteinaemia

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

45 Years to 70 Years
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Bristol-Myers Squibb
Study Director: László Erős, MD Sanofi-aventis, Hungary
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP